Two Sigma Advisers LP Grows Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Two Sigma Advisers LP raised its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 240.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,236,200 shares of the company's stock after purchasing an additional 873,200 shares during the period. Two Sigma Advisers LP owned 1.02% of 10x Genomics worth $17,752,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of TXG. Entropy Technologies LP grew its stake in shares of 10x Genomics by 285.6% in the 4th quarter. Entropy Technologies LP now owns 37,595 shares of the company's stock valued at $540,000 after buying an additional 27,844 shares during the period. SG Americas Securities LLC lifted its holdings in 10x Genomics by 209.8% during the fourth quarter. SG Americas Securities LLC now owns 73,046 shares of the company's stock worth $1,049,000 after acquiring an additional 49,468 shares during the period. Alberta Investment Management Corp bought a new stake in 10x Genomics during the fourth quarter worth $3,206,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of 10x Genomics in the 4th quarter worth approximately $326,000. Finally, Barclays PLC raised its holdings in shares of 10x Genomics by 11.7% in the 3rd quarter. Barclays PLC now owns 602,536 shares of the company's stock worth $13,605,000 after purchasing an additional 63,079 shares during the period. 84.68% of the stock is owned by institutional investors.

10x Genomics Stock Performance

Shares of TXG traded up $0.33 on Tuesday, hitting $8.50. 618,073 shares of the stock traded hands, compared to its average volume of 2,382,862. The company has a market capitalization of $1.05 billion, a PE ratio of -5.59 and a beta of 1.94. The business has a 50 day simple moving average of $8.54 and a 200 day simple moving average of $11.97. 10x Genomics, Inc. has a one year low of $6.78 and a one year high of $24.76.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The business had revenue of $154.88 million during the quarter, compared to the consensus estimate of $131.91 million. During the same quarter in the previous year, the firm posted ($0.50) EPS. The firm's revenue was down 2.3% on a year-over-year basis. On average, equities analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TXG has been the topic of a number of analyst reports. Citigroup lowered their target price on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Stifel Nicolaus reduced their target price on 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. JPMorgan Chase & Co. cut their price target on shares of 10x Genomics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Wall Street Zen upgraded shares of 10x Genomics from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Finally, UBS Group dropped their target price on shares of 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, 10x Genomics currently has a consensus rating of "Hold" and a consensus price target of $15.81.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.